文献速递浆细胞疾病

1q21扩增多发性骨髓瘤对MCL-1靶向治疗高度敏感

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
PubMed 文献 · Blood Adv · 2019-01-01

研究在31株人骨髓瘤细胞系和47例初诊MM患者骨髓标本中检测MCL-1抑制剂S63845单药或联合BCL-2/BCL-XL抑制剂的细胞活力效应。首次证明1q21扩增的MM细胞对MCL-1抑制显著更敏感,且高血清β2微球蛋白和肾功能不全与敏感性增加相关;联合BH3模拟物可协同增强凋亡。

要点

  • 1q21扩增可预测MM对MCL-1抑制剂S63845的高敏感性。
  • 高β2微球蛋白和肾功能不全与MCL-1抑制剂敏感性增加相关。
  • S63845联合BCL-2或BCL-XL抑制剂可协同增强凋亡。

核心结论

  • 1q21扩增可识别对MCL-1抑制剂治疗高度敏感的MM亚群,可作为指导治疗选择的预测标志物。

研究设计与样本

  • 在31株人骨髓瘤细胞系和47例初诊MM患者骨髓抽吸液中检测S63845单药或联合ABT-199、A-1155463或A-1331852对细胞活力的影响。

主要发现

  • 首次证明1q21扩增的MM患者细胞对MCL-1抑制显著更敏感。
  • 高血清β2微球蛋白水平和肾功能不全与MCL-1抑制剂敏感性增加相关,部分独立于1q21状态。
  • S63845与其他BH3模拟物联合较单药协同增强凋亡,且对MCL-1抑制单药不敏感的大部分MM对联合方案敏感。

临床怎么用

  • 可将1q21扩增作为预测标志物,筛选可能从MCL-1抑制剂治疗中获益的MM患者。
  • MCL-1抑制剂与其他BH3模拟物联合可能克服单药不敏感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prosurvival BCL-2 family proteins are potent inhibitors of apoptosis and often overexpressed in lymphoid malignancies. In multiple myeloma (MM), MCL-1 expression contributes to survival of malignant plasma cells, and overexpression correlates with poor prognosis. In this study, we investigated whether sensitivity to the novel MCL-1 inhibitor S63845 could be predicted using cytogenetics, focusing on amplification of 1q21, the chromosomal region that contains the MCL1 locus. In addition, we studied the relation of MCL-1 inhibitor sensitivity with other diagnostic characteristics and BCL-2 family protein expression. In 31 human myeloma cell lines and in bone marrow aspirates from 47 newly diagnosed MM patients, we measured the effect of S63845 alone, or combined with BCL-2 inhibitor ABT-199 (venetoclax), and BCL-XL inhibitor A-1155463 or A-1331852 on cell viability. We demonstrated for the first time that MM cells from patients with 1q21 amplification are significantly more sensitive to inhibition of MCL-1. We suggest that this increased sensitivity results from high relative MCL1 expression resulting from amplification of 1q21. Additionally, and partially independent from 1q21 status, high serum β2 microglobulin level and presence of renal insufficiency correlated with increased sensitivity to MCL-1 inhibitor treatment. Combining S63845 with other BH3 mimetics synergistically enhanced apoptosis compared with single inhibitors, and sensitivity to inhibitor combinations was found in a large proportion of MM insensitive to MCL-1 inhibition alone. Collectively, our data indicate that amplification of 1q21 identifies an MM subset highly sensitive to MCL-1 inhibitor treatment and can be used as a predictive marker to guide selection of therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Slomp A, Moesbergen LM, Gong JN, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 2019. PMID: 31856269. doi:10.1182/bloodadvances.2019000702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。